

Mammalian Neuronal Sodium Channel Blocker μ -Conotoxin BullIB Has a Structured N-Terminus That Influences Potency

Zhihe Kuang,^{†,‡} Min-Min Zhang,[‡] Kallol Gupta,[§] Joanna Gajewiak,[⊥] Jozsef Gulyas,^{||} Padmanabhan Balaram,[§] Jean E. Rivier,^{||} Baldomero M. Olivera,[⊥] Doju Yoshikami,[⊥] Grzegorz Bulaj,[⊥] and Raymond S. Norton^{*,||}

[†]The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria, 3052, Australia

[‡]Department of Biology, University of Utah, Salt Lake City, Utah 84112, United States

[§]Molecular Biophysics Unit, Indian Institute of Science, Bangalore, 560 012, India


^{||}The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037, United States

[⊥]Department of Medicinal Chemistry, College of Pharmacy, University of Utah, Salt Lake City, Utah 84108, United States

^{*}Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia

S Supporting Information

ABSTRACT: Among the μ -conotoxins that block vertebrate voltage-gated sodium channels (VGSCs), some have been shown to be potent analgesics following systemic administration in mice. We have determined the solution structure of a new representative of this family, μ -BullIB, and established its disulfide connectivities by direct mass spectrometric collision induced dissociation fragmentation of the peptide with disulfides intact. The major oxidative folding product adopts a 1–4/2–5/3–6 pattern with the following disulfide bridges: Cys5–Cys17, Cys6–Cys23, and Cys13–Cys24. The solution structure reveals that the unique N-terminal extension in μ -BullIB, which is also present in μ -BuIIIA and μ -BuIIIC but absent in other μ -conotoxins, forms part of a short α -helix encompassing Glu3 to Asn8. This helix is packed against the rest of the toxin and stabilized by the Cys5–Cys17 and Cys6–Cys23 disulfide bonds. As such, the side chain of Val1 is located close to the aromatic rings of Trp16 and His20, which are located on the canonical helix that displays several residues found to be essential for VGSC blockade in related μ -conotoxins. Mutations of residues 2 and 3 in the N-terminal extension enhanced the potency of μ -BullIB for $\text{Na}_v1.3$. One analogue, [D-Ala2]BullIB, showed a 40-fold increase, making it the most potent peptide blocker of this channel characterized to date and thus a useful new tool with which to characterize this channel. On the basis of previous results for related μ -conotoxins, the dramatic effects of mutations at the N-terminus were unanticipated and suggest that further gains in potency might be achieved by additional modifications of this region.



One snails elaborate a variety of peptide toxins that have proven to be valuable probes of ion channel function.^{1–3} In particular, the μ -conotoxin family targets voltage-gated sodium channels (VGSCs), binding to the extracellular side of the pore (site 1) and preventing the passage of sodium ions.^{4,5} In mammals, nine different VGSC subtypes of the α -subunit ($\text{Na}_v1.1$ – 1.9) have been identified, each with different distributions in the body.⁴ Of particular interest are the neuronal subtypes implicated in the perception of pain^{6,7} as modulators of these subtypes may have potential therapeutic use as analgesics.^{7,8}

Of the nine α -subunits found in mammals, six bind tetrodotoxin (TTX) with high affinity (IC_{50} in the nanomolar range), and three, $\text{Na}_v1.5$, $\text{Na}_v1.8$, and $\text{Na}_v1.9$, are classified as TTX-resistant ($\text{IC}_{50} > 1 \mu\text{M}$). The first μ -conotoxin characterized, μ -GIIIA from *Conus geographus*, targets mainly the TTX-sensitive skeletal muscle subtype $\text{Na}_v1.4$.^{9,10} μ -PIIIA also has a strong preference for $\text{Na}_v1.4$ but can block other

TTX-sensitive subtypes as well, albeit with lower affinities.^{11–13} More recently, a group of μ -conotoxins was discovered that targets neuronal sodium channels with greater selectivity and potency than μ -GIIIA or μ -PIIIA.^{14–18} This group includes μ -SmIIIA, which irreversibly inhibited TTX-resistant sodium currents in amphibian sympathetic and dorsal root ganglion (DRG) neurons,¹⁴ as well as μ -KIIIA and μ -SIIIA.^{16,19} The selectivity of these and several other μ -conotoxins for $\text{Na}_v1.1$ through $\text{Na}_v1.8$ has recently been described in detail, and combinations of these peptides could be used to define Na_v1 contributions to action potentials in sciatic nerve.²⁰

The μ -conotoxins also have potential in the treatment of chronic pain. Micromolar concentrations of μ -SIIIA slowly

Received: December 7, 2012

Accepted: April 4, 2013

Published: April 4, 2013

DHSR) have been excised by trypsin cleavage at the R-C5, K-N, R-G, R-D, and R-C23 peptide bonds. In addition, a proteolytic cleavage at the R-W bond was also observed. This meant that the tryptic peptide consisted of four individual peptide chains held together by three disulfide bonds, as shown in Figure 2D. Figure 2A shows the MS² CID fragmentation spectrum of the doubly charged species of this tryptic peptide. All the structures were obtained by directly querying the *m/z* and assigned charge state values against the native sequence of μ -BuIIIb, through DisConnect. The structures of the key ions, as obtained by DisConnect, are shown in Figure 2D. All experimental masses, rounded off to first decimal place, are within 0.1 Da of the theoretical values of the obtained structures; indeed, in determining the structures of the experimentally obtained ions through DisConnect, even with a window range as high as 0.5 Da, the assigned structures were the unique hits for each of the experimental values. Direct determination of the connectivity pattern was achieved by the MS³ fragmentation of two MS² ions. Figure 2B shows the CID MS³ fragmentation spectrum of 645.3. The structures of the obtained product ions are shown in Figure 2D. Among these product ions, the structure of 510.2 directly establishes the C13–C24 connectivity. To resolve the remaining connectivity patterns we turned to the CID MS³ spectrum of 995.3, as shown in Figure 2C. The structures of the obtained MS³ product ions, as derived through DisConnect, are shown in Figure 2D. The structure of 860.3 contains three peptide chains held by two disulfide bonds between four cysteine residues (C6, C13, C23, and C24). Since a connectivity between C13–C24 is already established, the other disulfide bond in 860.3 must be between C6–C23. Thus the overall connectivity of μ -BuIIIb is C5–C17/C6–C23/C13–C24.

NMR Spectroscopy. Good quality spectra were obtained for both μ -BuIIIb and [D-Ala2]BuIIIb. Broad NH chemical shift dispersion for both peptides indicated that they were well structured and adopted a single major conformation in solution. The amide and aromatic regions of 1D spectra of μ -BuIIIb at different temperatures are shown in Supplementary Figure S2A, and complete 1D spectra of [Ala2]BuIIIb and [D-Ala2]BuIIIb are shown in Supplementary Figure S2B–D. Chemical shift assignments and structural constraints have been deposited in the BioMagResBank²⁷ with accession numbers 18203 and 18206 for μ -BuIIIb and [D-Ala2]BuIIIb, respectively. Distance constraints were obtained from the intensities of the NOE cross-peaks at 5 °C and pH 5.5 for both μ -BuIIIb and [D-Ala2]BuIIIb, with a NOESY spectrum of μ -BuIIIb at 15 °C being used to resolve peak overlap. NOE statistics and connectivities plotted as a function of residue number are shown in Supplementary Figure S3.

Solution Structures. Table 1 summarizes the experimental constraints and structural statistics for μ -BuIIIb and [D-Ala2]BuIIIb. The structures fit well with experimentally derived distance and angle constraints and are well-defined over the entire length of the peptide. The angular order parameters for φ and ψ angles in the final ensemble of 20 structures for μ -BuIIIb were >0.8 except for the φ angle of Gly2 (Supplementary Figure S4), indicating that backbone dihedral angles are well-defined across the family of structures. The mean pairwise RMSD values of backbone heavy atoms over all residues for the families of μ -BuIIIb and [D-Ala2]BuIIIb were 0.54 and 0.59 Å, respectively. The ensemble of the μ -BuIIIb structures is shown in Figure 3A, and the closest-to-average structure is shown in Figure 3B. The final structures have been

Table 1. Structural Statistics for μ -BuIIIb and [D-Ala2]BuIIIb

	μ -BuIIIb	[D-Ala2]BuIIIb
no. of distance constraints	446	422
intraresidue ($i = j$)	210	203
sequential ($ i - j = 1$)	115	108
short ($1 < i - j < 6$)	77	70
long	44	41
no. of dihedral constraints	34	30
energy (kcal/mol) ^a		
E_{NOE}	13.5 ± 1.1	12.4 ± 0.7
deviations from ideal geometry ^b		
bonds (Å)	0.0048 ± 0.0002	0.0049 ± 0.0002
angles (deg)	0.6955 ± 0.0205	0.7201 ± 0.0372
impropers (deg)	0.5855 ± 0.0410	0.6005 ± 0.0549
mean global RMSD (Å) ^c		
backbone heavy atoms (N, C $^{\alpha}$, C $^{\prime}$)	0.54 ± 0.10	0.59 ± 0.13
all heavy atoms	1.62 ± 0.24	1.48 ± 0.22
Ramachandran plot ^d		
most favored (%)	85.6	88.6
allowed (%)	14.4	11.4
additionally allowed (%)	0	0
disallowed (%)	0	0

^aThe values for E_{NOE} are calculated from a square well potential with force constants of 50 kcal mol⁻¹ Å². ^bThe values for the bonds, angles, and impropers show the deviations from ideal values based on perfect stereochemistry. ^cMean pairwise RMSD over all residues calculated in MOLMOL. ^dAs determined by the program PROCHECK-NMR for all residues except Gly in μ -BuIIIb and D-Ala2 and Gly in [D-Ala2]BuIIIb.

deposited in the Protein Data Bank (PDB)²⁸ under ID codes 2LO9 and 2LOC for μ -BuIIIb and [D-Ala2]BuIIIb, respectively.

The unique N-terminal extension in μ -BuIIIb, which is also present in μ -BuIIIA and μ -BuIIIC but absent in other μ -conotoxins (Figure 1), forms part of a short α -helix in μ -BuIIIb (residues Glu3 to Asn8). The presence of medium-range NOEs [$d_{\text{aN}}(i, i+3)$, $d_{\text{a}\beta}(i, i+3)$, and $d_{\text{aN}}(i, i+4)$] in this region supports the helix observed (Supplementary Figure S3). This helix is packed against the remaining part of the toxin and is stabilized by the Cys5–Cys17 and Cys6–Cys23 disulfide bonds. As such, the side chain of Val1 is located at the outer edge of a π – π stacking formed by the aromatic rings of Trp16 and His20 (Figure 3B). Methyl NOEs of Val1 and C $^{\alpha}$ proton NOEs of Gly2 to the Trp16 ring protons were observed. In the final 20 structures, the φ angle of Gly2 has a broad range distribution ($140 \pm 42^\circ$) and is predominantly (16 structures) positive (Supplementary Figure S5). This indicates that the N-terminal residues Val1 and Gly2 have a preferred conformation but still retain a degree of flexibility. In the surface model of μ -BuIIIb (Figure 3C), Val1 and the aromatic rings of Trp16 and His20 form a prominent solvent-exposed hydrophobic patch that is adjacent to charged residues Arg15, Arg18, Asp19, and Arg22, equivalent residues of which were found to be critical in VGSC blocking of μ -KIIIA.¹⁷ Superimposition of the μ -BuIIIb structure with structures determined previously for μ -KIIIA, μ -SIIIA, μ -SmIIIA, and μ -TIIIA reveals that none of these toxins has structural equivalents of Val1 and Gly2 in μ -BuIIIb (Figure 4). Both μ -SIIIA and μ -SmIIIA have two residues N-terminal to the first Cys, and Arg2 of μ -SmIIIA corresponds to Arg4 of μ -BuIIIb (Figure 1); the structure of the N-terminal




Figure 3. μ -BullIIB structure. (A) Stereo views of the family of 20 final structures, superimposed over backbone heavy atoms. Disulfide bonds are colored gold. (B) Stereo ribbon views of the closest-to-average structure. Disulfide bonds are colored gold. Side chains of selected residues are shown and labeled. (C) Surface representation of μ -BullIIB, with Arg and Lys residues colored blue; Asp and Glu residues colored red; Cys, His, Trp, and Val residues colored yellow; and all other residues colored gray. Two views rotated by 90° about the vertical axis are shown.

residues in μ -SIII A shows no similarity to that of μ -BullIIB (Figure 4B), although the structure of μ -SmIII A is more similar (Figure 4C). While μ -TIII A has three residues in its N-terminus before the first cysteine, only one residue less than μ -BullIIB (Figure 1), it has large structural differences in the N-terminal region and the C-terminal α -helix region compared to μ -BullIIB (Figure 4D).

μ -BullIIB residues Gly9 to Gly12 form the second helical (3_{10} -like) region, containing the side chains of two basic residues (Lys10 and Arg11). Gly9 has a positive φ value, whereas that of Gly12 is negative. Interestingly, while the residue numbers between the second and third cysteines vary from five to eight among μ -BullIII A, μ -BullIIB and μ -BullIIC, Lys10 and Arg11 are conserved (Figure 1). These two residues do not have basic residue counterparts in μ -KIII A or μ -SIII A, which only have one and three residues, respectively, between the second and third cysteines (Figures 1 and 4). μ -Conotoxins SmIII A, GIII A, PIII A, and TIII A have five residues in this loop and have one to two basic residues (Figure 1).

From residues Cys13 to Cys24, μ -BullIIB shares high sequence conservation with other μ -conotoxins, including μ -KIII A, μ -SIII A, and μ -SmIII A, but less conservation with μ -GIII A, μ -PIII A, and μ -TIII A (Figure 1). Structurally this part of the toxin forms a C-terminal α -helix (residues 15–20). μ -BullIIB, as well as μ -BullIII A and μ -BullIIC, has three residues but other μ -conotoxins have four residues between the third and




Figure 4. Comparison of μ -BullIIB and other μ -conotoxin structures. The closest-to-average structures of μ -BullIIB (blue) and (A) μ -KIII A (green,³⁸ PDB 2LXG), (B) μ -SIII A (yellow,¹⁹ BMRB 20023), (C) μ -SmIII A (orange,¹⁵ PDB 1Q2J), (D) μ -TIII A (cyan,¹⁸ BMRB 20024) are superimposed over backbone heavy atoms (N, C $^{\alpha}$, and C') of residues 5,6,13,14–24 for μ -BullIIB (residues 1,2,4,6–16 for μ -KIII A; residues 3,4,8,10–20 for μ -SIII A; residues 3,4,10,12–22 for μ -SmIII A; and residues 4,5,11,12–22 for μ -TIII A). N- and C-termini of the molecules are labeled.

the fourth cysteine residues (Cys13 and Cys17 in μ -BullIIB, Figure 1), resulting in a shorter loop in the μ -BullIIB structure preceding the C-terminal α -helix (Figure 4). The large structural differences in the C-terminal α -helix between μ -BullIIB and μ -TIII A (Figure 4D) are probably due to the fact that μ -TIII A lacks the Trp and His residues conserved in μ -BullIIB (Trp16 and His20), μ -KIII A, μ -SIII A, and μ -SmIII A and that the loop between the fourth and fifth cysteines is one residue shorter (Figure 1). Basic residues Arg15 (the homologous residue in μ -KIII A, μ -SIII A, and μ -SmIII A is Lys) and Arg18, as well as the acidic residue Asp19, reside on the C-terminal α -helix. Another basic residue, Arg22, is nearby. These charged residues are conserved in μ -conotoxins, and corresponding residues have been found to be important for activities against VGSCs.^{2,4,5,8} μ -BullIIB is a highly basic polypeptide as a result of its five Arg and two Lys residues. Consequently, the surface of μ -BullIIB is highly positively charged (Figure 3C).

Comparison of μ -BullIIB and [D-Ala2]BullIIB. Backbone H^N and H $^{\alpha}$ proton chemical shift differences between μ -BullIIB and [D-Ala2]BullIIB (Figure 5A) indicated that the D-Ala substitution of Gly2 affected predominantly the chemical shifts of residues 1–6, as well as the H^N chemical shift of Ser21, which is distant from Gly2 in the amino acid sequence but is in very close proximity in the three-dimensional structure. Interestingly, the backbone amide proton chemical shifts of Gly9, Gly12, and Gly14 were all affected, even though these residues are structurally distant from the substitution site; these perturbations further emphasize that the N-terminal region is coupled structurally to the rest of the molecule and that changes there are sensed throughout the molecule. An overlay of the fingerprint regions of 2D NOESY spectra of μ -BullIIB and [D-Ala2]BullIIB showed that NOE connections in μ -BullIIB




Figure 5. Comparison of μ -BuIIIb and [D-Ala2]BuIIIb structures. (A) Backbone H^N and H^α chemical shift differences between μ -BuIIIb and [D-Ala2]BuIIIb. (B) Stereo views of 20 final structures of μ -BuIIIb (blue) and [D-Ala2]BuIIIb (pink) superimposed over backbone heavy atoms. (C) Stereo views of the closest-to-average structures of μ -BuIIIb (blue) and [D-Ala2]BuIIIb (pink) superimposed over backbone heavy atoms. Side chains of Val1, Trp16, His20, and the D-Ala2 substitution are shown and labeled.

are maintained in [D-Ala2]BuIIIb (Supplementary Figure S6). For example, methyl NOEs of Val1 to the aromatic ring protons of Trp16 were found in both μ -BuIIIb and [D-Ala2]BuIIIb, whereas H^α NOEs of Gly2 to Trp16 in μ -BuIIIb are replaced by the H^α and methyl NOEs of D-Ala2 to Trp16 in [D-Ala2]BuIIIb. As suggested by the NMR data, superimposition of the final families (Figure 5B) or closest-to-average structures (Figure 5C) of μ -BuIIIb and [D-Ala2]BuIIIb over backbone heavy atoms showed that the backbones align very well, with RMSD values of 0.79 Å over all residues and 0.66 Å over residues 3–24 (for the closest-to-average structures). The two structures have only minor conformational differences in the region of residues 1–6 and the aromatic side chains of Trp16 and His20, while the rest of the structures are essentially identical.

Functional Activities of [D-Ala2]BuIIIb and Other N-Terminal Analogues in Blocking $Na_v1.3$. Synthetic μ -BuIIIb and N-terminal analogues thereof were tested for their ability to inhibit voltage-gated sodium currents of voltage-clamped *Xenopus* oocytes expressing $Na_v1.3$, as described in

Supporting Information. Representative control and peptide-blocked sodium current traces for μ -BuIIIb and [D-Ala2]BuIIIb are illustrated in Figure 6A and C, and corresponding plots of the time course of inhibition are shown in Figure 6B and D. For each peptide, the onset of block was fit to a single exponential to obtain the observed rate constant, k_{obs} , and k_{obs} values were determined at different peptide concentrations. The plots of k_{obs} versus [peptide] are shown in Supplementary Figure S7, from which the value of k_{on} for each peptide was obtained from the slope of the line (see Supporting Information), and these are given in Table 2. The k_{off} values obtained by direct measurements of the rates of washout of the toxins (see Supporting Information) are listed in Table 2 along with the corresponding K_d values. In principle, the y -intercepts in Supplementary Figure S7 can provide k_{off} values; however, those obtained were (mean \pm SD) -0.084 ± 0.832 and $0.021 \pm 0.085 \text{ min}^{-1}$ for [D-Ala2]BuIIIb and μ -BuIIIb, respectively, and are not statistically meaningful.

Block by $3.3 \mu\text{M}$ [D-Ala2]BuIIIb is incomplete (e.g., Figure 6D), with a block of $94 \pm 2\%$ (mean \pm SD, $N = 6$ oocytes).




Figure 6. Block of $\text{Na}_v1.3$ by $\mu\text{-BuIIIB}$ and $[\text{D-Ala2}]\text{BuIIIB}$. Oocytes expressing $\text{Na}_v1.3$ were voltage clamped at -80 mV, and sodium channels were activated with a voltage step to -10 mV as described in Supporting Information. Representative sodium currents before (gray trace) and during (black trace) exposure to 3.3 μM of $\mu\text{-BuIIIB}$ (A) or $[\text{D-Ala2}]\text{BuIIIB}$ (C). Representative time course of block and recovery, where the bar above each plot indicates when 3.3 μM of $\mu\text{-BuIIIB}$ (B) or $[\text{D-Ala2}]\text{BuIIIB}$ (C) was present. The traces in the presence of toxin in panels A and C were obtained at the peak of block in panels B and D, respectively.

Table 2. Comparison of the Inhibition of $\text{Na}_v1.3$ by $\mu\text{-BuIIIB}$ and N-Terminal Analogues^a

peptide	k_{on} ($\mu\text{M min}^{-1}$)	k_{off} (min^{-1})	K_d (μM)
$\mu\text{-BuIIIB}$	0.085 ± 0.01	0.017 ± 0.007	0.2 ± 0.086
$[\text{Ala1}]\text{BuIIIB}$	0.014 ± 0.004	0.01 ± 0.003	0.71 ± 0.3
$[\text{D-Ala2}]\text{BuIIIB}$	0.83 ± 0.05	0.004 ± 0.0017	0.0048 ± 0.002
$[\text{Ala2}]\text{BuIIIB}$	0.25 ± 0.03	0.009 ± 0.002	0.036 ± 0.009
$[\text{Ala3}]\text{BuIIIB}$	0.46 ± 0.03	0.007 ± 0.0013	0.015 ± 0.003
$[\text{Ala4}]\text{BuIIIB}$	0.056 ± 0.008	0.01 ± 0.002	0.18 ± 0.044
$[\text{des1-4}]\text{BuIIIB}$	0.47 ± 0.06	0.025 ± 0.005	0.053 ± 0.013

^aRate constants were determined as described in Supporting Information. K_d was determined from $k_{\text{off}}/k_{\text{on}}$. Data for $\mu\text{-BuIIIB}$ are from Wilson et al.²⁰

However, with a K_d of 4.8 nM (Table 2), $>99\%$ block is expected, assuming a dose–response relationship described by the Langmuir adsorption isotherm: fraction blocked = $1/(1 + (K_d/[\text{toxin}]))$. This suggests that a “residual current” remains at saturating peptide concentrations; indeed, when tests were conducted at a 10-fold higher concentration of 33 μM , the residual current persisted (not shown). At least two possible explanations may account for such a residual current: (A) there are two populations of channels, with the majority being sensitive to the peptide and a small minority being insensitive, or (B) the blocking efficacy of the peptide is less than 100%, such as that observed when $\mu\text{-KIIIA}$ and its derivatives were tested on $\text{Na}_v1.2$ and $\text{Na}_v1.4$,^{29–31} and when $\mu\text{-CnIIIA}$ was tested on $\text{Na}_v1.4$.³² Further tests, which are beyond the scope of the present study, are necessary to pinpoint the mechanism responsible for the small ($\sim 5\%$) residual current observed with $[\text{D-Ala2}]\text{BuIIIB}$ and $\text{Na}_v1.3$.

Five additional N-terminal analogues of $\mu\text{-BuIIIB}$ were synthesized and tested on $\text{Na}_v1.3$. Four of these represent an alanine scan of the four N-terminal residues of $\mu\text{-BuIIIB}$, and the fifth, $[\text{des1-4}]\text{BuIIIB}$, was $\mu\text{-BuIIIB}$ bereft of its N-terminal four residues. The activities of these analogues, summarized in Table 2, show that the rank order of their K_d values in blocking $\text{Na}_v1.3$ was $[\text{D-Ala2}]\text{BuIIIB} < [\text{Ala3}]\text{BuIIIB} < [\text{Ala2}]\text{BuIIIB} < [\text{des1-4}]\text{BuIIIB} < [\text{Ala4}]\text{BuIIIB} < \text{BuIIIB} < [\text{Ala1}]\text{BuIIIB}$. $[\text{D-Ala2}]\text{BuIIIB}$ was the most potent in blocking $\text{Na}_v1.3$ and had the fastest on-rate and slowest off-rate.

Conclusions. The solution structures determined in this study for $\mu\text{-BuIIIB}$ and $[\text{D-Ala2}]\text{BuIIIB}$ show, rather unexpectedly, that the N-terminal residues in $\mu\text{-BuIIIB}$ are in close proximity to a region of these peptides that has been shown previously to be important for VGSC-blocking activity. The functional significance of this close proximity is underscored by the dramatic effects of modifications of the N-terminal extension on activity. Mutations in Gly2 or Glu3 significantly enhance the potency of $\mu\text{-BuIIIB}$ for $\text{Na}_v1.3$, with one analogue, $[\text{D-Ala2}]\text{BuIIIB}$, showing a 40-fold increase. Indeed, $[\text{D-Ala2}]\text{BuIIIB}$ appears to be the most potent peptide blocker of the $\text{Na}_v1.3$ channel characterized to date.

The 8-fold difference in K_d between the D-Ala2 and L-Ala2 analogues also highlights the importance of the local conformation in this region of the molecule in generating high potency against $\text{Na}_v1.3$. The D-Ala2 substitution is more likely to stabilize a type II β -turn conformation, with D-Ala mimicking the positive φ -angle of Gly2 in $\mu\text{-BuIIIB}$ (Supplementary Figure S5) in a way that L-Ala cannot.^{33,34} Moreover, this reinforces the view that the N-terminus of $\mu\text{-BuIIIB}$ adopts a well-defined structure, as indicated by our NMR data. The 13-fold enhancement in K_d for $\text{Na}_v1.3$ generated by the substitution of Glu3 by Ala is less likely to have a structural basis and may indicate that Glu3 engages in unfavorable interactions with $\text{Na}_v1.3$, implying that further manipulation of this position in $\mu\text{-BuIIIB}$ may have even more beneficial effects on the potency and perhaps also the selectivity of this toxin.

Intriguingly, deletion of all four N-terminal residues in $\mu\text{-BuIIIB}$ causes a 4-fold improvement in the K_d for $\text{Na}_v1.3$. This implies that some of the other substitutions in $\mu\text{-BuIIIB}$ relative to $\mu\text{-KIIIA}$, in particular those in the first inter-cysteine loop (Figure 1), are favorable for $\text{Na}_v1.3$ blockade and suggests that a combination of those substitutions in $\mu\text{-BuIIIB}$ with further manipulation of the N-terminal four residues would be beneficial in generating an even more potent and selective $\text{Na}_v1.3$ blocker from this peptide.

$\mu\text{-BuIIIA}$, $\mu\text{-BuIIIB}$, and $\mu\text{-BuIIIC}$ were shown recently to block $\text{Na}_v1.4$ exogenously expressed in oocytes.²³ In more recent experiments, $\mu\text{-BuIIIA}$ and $\mu\text{-BuIIIB}$ were tested on $\text{Na}_v1.1$ through 1.8 expressed in oocytes, where it was observed that $\mu\text{-BuIIIA}$ was by and large less potent than $\mu\text{-BuIIIB}$, and the latter’s rank order of affinity (K_d or IC_{50} , prefix “r” and “m” represent rat and mouse) was $r\text{Na}_v1.4 \approx r\text{Na}_v1.2 < r\text{Na}_v1.3 \approx r\text{Na}_v1.1 < m\text{Na}_v1.6 < r\text{Na}_v1.5$, with no block of $r\text{Na}_v1.7$ or $r\text{Na}_v1.8$ observed when tested at a concentration of 100 μM .²⁰ The experiments described here focused on $\text{Na}_v1.3$, where the $[\text{Gly2D-Ala}]$ mutation was observed to increase $\mu\text{-BuIIIB}$ ’s k_{on} by 10-fold and decrease its k_{off} by 4-fold, such that the K_d was decreased 40-fold by the substitution of D-Ala for Gly at position 2 of $\mu\text{-BuIIIB}$ (Table 2). Experiments are underway to examine how the mutation affects $\mu\text{-BuIIIB}$ ’s affinity for the other Na_v1 isoforms.

Specific disulfide mapping for μ -BuIIIB, which belongs to the M5 branch of the μ -conotoxin family (so-called because of the presence of five residues in the third and final inter-cysteine loop, as shown in Figure 1), had not been conducted until now. A 1–4/2–5/3–6 pattern of disulfide connectivities was assumed on the basis of sequence alignment with the closely related μ -conotoxins in the M4 branch, and solution structures of μ -SmIIIA,¹⁵ μ -SIIIA,¹⁹ μ -KIIIA,³⁵ and most recently μ -CnIIIC³⁶ were solved assuming the canonical disulfide connectivity pattern. In this study we have verified that the 1–4/2–5/3–6 pattern is correct for the major product of *in vitro* oxidative refolding. In contrast, recent studies on μ -KIIIA^{37,38} showed that the thermodynamically favored product of oxidative folding *in vitro* has 1–5/2–4/3–6 disulfide connectivity. We note that μ -KIIIA has a shorter first loop compared with other M5 μ -conotoxins, with only one amino acid residue between the second and third cysteine residues (Figure 1), and this is likely to influence folding and thus disulfide bridge formation.

Our observations for μ -BuIIIB also have important consequences for attempts to recapitulate the activity of the μ -conotoxins in truncated and stabilized peptide analogues. Recent attempts along these lines^{39,40} have focused on incorporating the residues identified as important for μ -KIIIA blockade of VGSC^{17,22} on a helical scaffold as found in the full-length toxin.³⁵ The significant effects of modifications at the N-terminus of μ -BuIIIB suggest that elements of this region of the μ -conotoxins might be incorporated to optimize the blockade of certain VGSC subtypes such as Na_v1.3.

METHODS

All materials and methods are described in the Supporting Information.

ASSOCIATED CONTENT

Supporting Information

Full details of methods, as well as Supplementary Figures S1–S16 and Supplementary Table S1. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Accession Codes

Chemical shift assignments for μ -BuIIIB and [D-Ala2]BuIIIB have been deposited in the BioMagResBank with accession numbers 18203 and 18206, respectively. NMR solution structures of μ -BuIIIB and [D-Ala2]BuIIIB have been deposited in the Protein Data Bank (PDB) under ID codes 2LO9 and 2LOC, respectively.

AUTHOR INFORMATION

Corresponding Author

*E-mail: ray.norton@monash.edu.

Present Address

[#]Institute of Biomedicine, Jinan University, Guangzhou 510632, China.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank A. Goldin (University of California, Irvine) for the rat Na_v1.3, rat Na_v1.4, and mouse Na_v1.6 clones; G. Mandel (Howard Hughes Medical Institute, Portland, OR) for the rat Na_v1.7 clone; and L. Azam (University of Utah) for producing cRNA from these clones. We also thank B. Green and K. Gowd

for helpful discussions, and A. Redding, J. Erchegeyi, C. Miller, and W. Low for technical assistance. This work was supported in part by grants from the Australian Research Council (DP1094212 to R.S.N., B.M.O., and G.B.) and the National Institute of General Medical Sciences grants GM 48677 (to G.B., B.M.O., and D.Y.). K.G. acknowledges CSIR, Government of India, for a senior research fellowship. The work at Bangalore (IISc, India) is supported by grants from the Department of Biotechnology, Government of India. R.S.N. acknowledges fellowship support from the Australian National Health and Medical Research Council.

REFERENCES

- (1) Terlau, H., and Olivera, B. M. (2004) *Conus* venoms: a rich source of novel ion channel-targeted peptides. *Physiol. Rev.* 84, 41–68.
- (2) Norton, R. S., and Olivera, B. M. (2006) Conotoxins down under. *Toxicon* 48, 780–798.
- (3) Han, T. S., Teichert, R. W., Olivera, B. M., and Bulaj, G. (2008) *Conus* venoms - a rich source of peptide-based therapeutics. *Curr. Pharm. Des.* 14, 2462–2479.
- (4) French, R. J., and Terlau, H. (2004) Sodium channel toxins—receptor targeting and therapeutic potential. *Curr. Med. Chem.* 11, 3053–3064.
- (5) French, R. J., Yoshikami, D., Sheets, M. F., and Olivera, B. M. (2010) The tetrodotoxin receptor of voltage-gated sodium channels—perspectives from interactions with μ -conotoxins. *Mar. Drugs* 8, 2153–2161.
- (6) Cummins, T. R., Sheets, P. L., and Waxman, S. G. (2007) The roles of sodium channels in nociception: Implications for mechanisms of pain. *Pain* 131, 243–257.
- (7) Dib-Hajj, S. D., Cummins, T. R., Black, J. A., and Waxman, S. G. (2010) Sodium channels in normal and pathological pain. *Annu. Rev. Neurosci.* 33, 325–347.
- (8) Norton, R. S. (2010) μ -Conotoxins as leads in the development of new analgesics. *Molecules* 15, 2825–2844.
- (9) Cruz, L. J., Gray, W. R., Olivera, B. M., Zeikus, R. D., Kerr, L., Yoshikami, D., and Moczydlowski, E. (1985) *Conus geographus* toxins that discriminate between neuronal and muscle sodium channels. *J. Biol. Chem.* 260, 9280–9288.
- (10) Li, R. A., Ennis, I. L., Xue, T., Nguyen, H. M., Tomaselli, G. F., Goldin, A. L., and Marban, E. (2003) Molecular basis of isoform-specific μ -conotoxin block of cardiac, skeletal muscle, and brain Na⁺ channels. *J. Biol. Chem.* 278, 8717–8724.
- (11) Shon, K. J., Olivera, B. M., Watkins, M., Jacobsen, R. B., Gray, W. R., Floresca, C. Z., Cruz, L. J., Hillyard, D. R., Brink, A., Terlau, H., and Yoshikami, D. (1998) μ -Conotoxin PIIIA, a new peptide for discriminating among tetrodotoxin-sensitive Na channel subtypes. *J. Neurosci.* 18, 4473–4481.
- (12) Nielsen, K. J., Watson, M., Adams, D. J., Hammarstrom, A. K., Gage, P. W., Hill, J. M., Craik, D. J., Thomas, L., Adams, D., Alewood, P. F., and Lewis, R. J. (2002) Solution structure of μ -conotoxin PIIIA, a preferential inhibitor of persistent tetrodotoxin-sensitive sodium channels. *J. Biol. Chem.* 277, 27247–27255.
- (13) Safo, P., Rosenbaum, T., Shcherbatko, A., Choi, D. Y., Han, E., Toledo-Aral, J. J., Olivera, B. M., Brehm, P., and Mandel, G. (2000) Distinction among neuronal subtypes of voltage-activated sodium channels by μ -conotoxin PIIIA. *J. Neurosci.* 20, 76–80.
- (14) West, P. J., Bulaj, G., Garrett, J. E., Olivera, B. M., and Yoshikami, D. (2002) μ -conotoxin SmIIIA, a potent inhibitor of tetrodotoxin-resistant sodium channels in amphibian sympathetic and sensory neurons. *Biochemistry* 41, 15388–15393.
- (15) Keizer, D. W., West, P. J., Lee, E. F., Yoshikami, D., Olivera, B. M., Bulaj, G., and Norton, R. S. (2003) Structural basis for tetrodotoxin-resistant sodium channel binding by μ -conotoxin SmIIIA. *J. Biol. Chem.* 278, 46805–46813.
- (16) Bulaj, G., West, P. J., Garrett, J. E., Watkins, M., Zhang, M. M., Norton, R. S., Smith, B. J., Yoshikami, D., and Olivera, B. M. (2005)

Novel conotoxins from *Conus striatus* and *Conus kinoshitai* selectively block TTX-resistant sodium channels. *Biochemistry* 44, 7259–7265.

(17) Zhang, M. M., Green, B. R., Catlin, P., Fiedler, B., Azam, L., Chadwick, A., Terlau, H., McArthur, J. R., French, R. J., Gulyas, J., Rivier, J. E., Smith, B. J., Norton, R. S., Olivera, B. M., Yoshikami, D., and Bulaj, G. (2007) Structure/function characterization of μ -conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. *J. Biol. Chem.* 282, 30699–30706.

(18) Lewis, R. J., Schroeder, C. I., Ekberg, J., Nielsen, K. J., Loughnan, M., Thomas, L., Adams, D. A., Drinkwater, R., Adams, D. J., and Alewood, P. F. (2007) Isolation and structure-activity of μ -conotoxin TIIIA, a potent inhibitor of tetrodotoxin-sensitive voltage-gated sodium channels. *Mol. Pharmacol.* 71, 676–685.

(19) Yao, S., Zhang, M. M., Yoshikami, D., Azam, L., Olivera, B. M., Bulaj, G., and Norton, R. S. (2008) Structure, dynamics, and selectivity of the sodium channel blocker μ -conotoxin SIIIA. *Biochemistry* 47, 10940–10949.

(20) Wilson, M. J., Yoshikami, D., Azam, L., Gajewiak, J., Olivera, B. M., Bulaj, G., and Zhang, M. M. (2011) μ -Conotoxins that differentially block sodium channels Na_v1.1 through 1.8 identify those responsible for action potentials in sciatic nerve. *Proc. Natl. Acad. Sci. U.S.A.* 108, 10302–10307.

(21) Green, B. R., Catlin, P., Zhang, M. M., Fiedler, B., Bayudan, W., Morrison, A., Norton, R. S., Smith, B. J., Yoshikami, D., Olivera, B. M., and Bulaj, G. (2007) Conotoxins containing nonnatural backbone spacers: cladistic-based design, chemical synthesis, and improved analgesic activity. *Chem. Biol.* 14, 399–407.

(22) McArthur, J. R., Singh, G., McMaster, D., Winkfein, R., Tieleman, D. P., and French, R. J. (2011) Interactions of key charged residues contributing to selective block of neuronal sodium channels by μ -conotoxin KIIIA. *Mol. Pharmacol.* 80, 573–584.

(23) Holford, M., Zhang, M. M., Gowd, K. H., Azam, L., Green, B. R., Watkins, M., Ownby, J. P., Yoshikami, D., Bulaj, G., and Olivera, B. M. (2009) Pruning nature: Biodiversity-derived discovery of novel sodium channel blocking conotoxins from *Conus bullatus*. *Toxicon* 53, 90–98.

(24) Catterall, W. A., Goldin, A. L., and Waxman, S. G. (2005) International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. *Pharmacol. Rev.* 57, 397–409.

(25) Gupta, K., Kumar, M., and Balaram, P. (2010) Disulfide bond assignments by mass spectrometry of native natural peptides: cysteine pairing in disulfide bonded conotoxins. *Anal. Chem.* 82, 8313–8319.

(26) Bhattacharyya, M., Gupta, K., Gowd, K. H., and Balaram, P. (2013) Rapid mass spectrometric determination disulfide connectivity in peptides and proteins. *Mol. Biosyst.*, DOI: 10.1039/C1033MB25534D.

(27) Ulrich, E. L., Akutsu, H., Doreleijers, J. F., Harano, Y., Ioannidis, Y. E., Lin, J., Livny, M., Mading, S., Maziuk, D., Miller, Z., Nakatani, E., Schulte, C. F., Tolmie, D. E., Kent Wenger, R., Yao, H., and Markley, J. L. (2008) BioMagResBank. *Nucleic Acids Res.* 36, D402–408.

(28) Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank. *Nucleic Acids Res.* 28, 235–242.

(29) Zhang, M. M., McArthur, J. R., Azam, L., Bulaj, G., Olivera, B. M., French, R. J., and Yoshikami, D. (2009) Synergistic and antagonistic interactions between tetrodotoxin and μ -conotoxin in blocking voltage-gated sodium channels. *Channels* 3, 32–38.

(30) Zhang, M. M., Han, T. S., Olivera, B. M., Bulaj, G., and Yoshikami, D. (2010) μ -conotoxin KIIIA derivatives with divergent affinities versus efficacies in blocking voltage-gated sodium channels. *Biochemistry* 49, 4804–4812.

(31) Zhang, M. M., Gruszczynski, P., Walewska, A., Bulaj, G., Olivera, B. M., and Yoshikami, D. (2010) Cooccupancy of the outer vestibule of voltage-gated sodium channels by μ -conotoxin KIIIA and saxitoxin or tetrodotoxin. *J. Neurophysiol.* 104, 88–97.

(32) Markgraf, R., Leipold, E., Schirmeyer, J., Paolini-Bertrand, M., Hartley, O., and Heinemann, S. H. (2012) Mechanism and molecular

basis for the sodium channel subtype specificity of μ -conopeptide CnIIIC. *Br. J. Pharmacol.* 167, 576–586.

(33) Pallaghy, P. K., Duggan, B. M., Pennington, M. W., and Norton, R. S. (1993) Three-dimensional structure in solution of the calcium channel blocker ω -conotoxin. *J. Mol. Biol.* 234, 405–420.

(34) Venkatachalam, C. M. (1968) Stereochemical criteria for polypeptides and proteins. V. Conformation of a system of three linked peptide units. *Biopolymers* 6, 1425–1436.

(35) Khoo, K. K., Feng, Z. P., Smith, B. J., Zhang, M. M., Yoshikami, D., Olivera, B. M., Bulaj, G., and Norton, R. S. (2009) Structure of the analgesic μ -conotoxin KIIIA and effects on the structure and function of disulfide deletion. *Biochemistry* 48, 1210–1219.

(36) Favreau, P., Benoit, E., Hocking, H. G., Carlier, L., D'hoedt, D., Leipold, E., Markgraf, R., Schlumberger, S., Cordova, M. A., Gaertner, H., Paolini-Bertrand, M., Hartley, O., Tytgat, J., Heinemann, S. H., Bertrand, D., Boelens, R., Stocklin, R., and Molgo, J. (2012) A novel μ -conopeptide, CnIIIC, exerts potent and preferential inhibition of Na_v1.2/1.4 channels and blocks neuronal nicotinic acetylcholine receptors. *Br. J. Pharmacol.* 166, 1654–1668.

(37) Poppe, L., Hui, J. O., Ligutti, J., Murray, J. K., and Schnier, P. D. (2012) PADLOC: a powerful tool to assign disulfide bond connectivities in peptides and proteins by NMR spectroscopy. *Anal. Chem.* 84, 262–266.

(38) Khoo, K. K., Gupta, K., Green, B. R., Zhang, M. M., Watkins, M., Olivera, B. M., Balaram, P., Yoshikami, D., Bulaj, G., and Norton, R. S. (2012) Distinct disulfide isomers of μ -conotoxins KIIIA and KIIIB block voltage-gated sodium channels. *Biochemistry* 51, 9826–9835.

(39) Khoo, K. K., Wilson, M. J., Smith, B. J., Zhang, M. M., Gulyas, J., Yoshikami, D., Rivier, J. E., Bulaj, G., and Norton, R. S. (2011) Lactam-stabilized helical analogues of the analgesic μ -conotoxin KIIIA. *J. Med. Chem.* 54, 7558–7566.

(40) Stevens, M., Peigneur, S., Dyubankova, N., Lescrinier, E., Herdewijn, P., and Tytgat, J. (2012) Design of bioactive peptides from naturally occurring μ -conotoxin structures. *J. Biol. Chem.* 287, 31382–31392.